TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, announced today it has completed its previously announced private placement of 4.4 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE